Clinical Trials · NCT03724981
A Study Comparing the Dulaglutide Pen and the Semaglutide Pen
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 312
- Start date
- Oct 2018
- Locations
- 14 sites, United States
- Primary endpoint
- Participant Preference Between 2 Injection Devices Based on Global Preference Item